Evidence map›Paper›PMID 33516523›Full record

ArticleThe Journal of allergy and clinical immunology2021

Atopic eczema in adulthood and mortality: UK population-based cohort study, 1998-2016.

Richard J Silverwood, Kathryn E Mansfield, Amy Mulick, Angel Y S Wong, Sigrún A J Schmidt, Amanda Roberts, Liam Smeeth, Katrina Abuabara, Sinéad M Langan

Abstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Novel insights into atopic dermatitis.The Journal of allergy and clinical immunology · 2023
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Richard J SilverwoodFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom; Centre for Longitudinal Studies, University College London Social Research Institute, University College London, London, United Kingdom.
Kathryn E MansfieldFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Amy MulickFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Angel Y S WongFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Sigrún A J SchmidtDepartment of Clinical Epidemiology and Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Amanda RobertsNottingham Support Group for Carers of Children with Eczema, Nottingham, United Kingdom.
Liam SmeethFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Katrina AbuabaraDepartment of Dermatology, University of California, San Francisco School of Medicine, San Francisco, Calif.
Sinéad M LanganFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom; Health Data Research UK, London, United Kingdom. Electronic address: Sinead.Langan@lshtm.ac.uk.

Funding

British Heart FoundationChief Scientist OfficeDepartment of HealthMedical Research CouncilWellcome TrustWellcome Trust 205039/Z/16/Z
6 · The paper itself

Abstract

backgroundAtopic eczema affects up to 10% of adults and is becoming more common globally. Few studies have assessed whether atopic eczema increases the risk of death.

objectiveWe aimed to determine whether adults with atopic eczema were at increased risk of death overall and by specific causes and to assess whether the risk varied by atopic eczema severity and activity.

methodsThe study was a population-based matched cohort study using UK primary care electronic health care records from the Clinical Practice Research Datalink with linked hospitalization data from Hospital Episode Statistics and mortality data from the Office for National Statistics from 1998 to 2016.

resultsA total of 526,736 patients with atopic eczema were matched to 2,567,872 individuals without atopic eczema. The median age at entry was 41.8 years, and the median follow-up time was 4.5 years. There was limited evidence of increased hazard for all-cause mortality in those with atopic eczema (hazard ratio = 1.04; 99% CI = 1.03-1.06), but there were somewhat stronger associations (8%-14% increased hazard) for deaths due to infectious, digestive, and genitourinary causes. Differences on the absolute scale were modest owing to low overall mortality rates. Mortality risk increased markedly with eczema severity and activity. For example, patients with severe atopic eczema had a 62% increased hazard (hazard ratio = 1.62; 99% CI = 1.54-1.71) for mortality compared with those without eczema, with the strongest associations for infectious, respiratory, and genitourinary causes.

conclusionThe increased hazards for all-cause and cause-specific mortality were largely restricted to those with the most severe or predominantly active atopic eczema. Understanding the reasons for these increased hazards for mortality is an urgent priority.

Indexed as

AdolescentAdultAgedAged, 80 and overCause of DeathCohort StudiesDermatitis, AtopicFemaleHumansMaleMiddle AgedUnited KingdomYoung AdultActivityatopic eczemacohort studyelectronic health care recordsmortalitypopulation-basedprimary careseverityUnited Kingdom

Identifiers

PMID33516523
PMCPMC8098860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.